Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.80 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.80 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.80 |
| ▸ | EGFR | P00533 | 1/20 | 0.70 |
| ▸ | RAF1 | P04049 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | GSK3B | P49841 | 1/20 | 0.70 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | BRAF | P15056 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5391299 | 0.89 | MAPK14 (1.00) | MAPK14CSNK1DCSNK1A1CSNK1EEGFR | |
| SCHEMBL5388978 | 0.86 | MAPK14 (1.00) | MAPK14CSNK1DCSNK1A1CSNK1EEGFR | |
| SCHEMBL30944213 | 0.85 | MAPK14 (0.74) | MAPK14CSNK1DCSNK1A1CSNK1EEGFR | |
| SCHEMBL5379805 | 0.85 | MAPK14 (1.00) | MAPK14CSNK1DCSNK1A1CSNK1EEGFR | |
| SCHEMBL30944230 | 0.84 | MAPK14 (0.72) | MAPK14CSNK1DCSNK1A1CSNK1EEGFR | |
| SCHEMBL5400284 | 0.83 | MAPK14 (0.70) | MAPK14CSNK1DCSNK1A1CSNK1EEGFR | |
| SCHEMBL30944233 | 0.83 | MAPK14 (0.70) | MAPK14CSNK1DCSNK1A1CSNK1EEGFR | |
| SCHEMBL30944242 | 0.83 | MAPK14 (0.70) | MAPK14CSNK1DCSNK1A1CSNK1EEGFR | |
| Gw434756X SCHEMBL5385166 | 0.82 | MAPK14 (1.00) | MAPK14CSNK1DCSNK1A1CSNK1EEGFR | |
| SCHEMBL30944208 | 0.80 | MAPK14 (0.70) | MAPK14CSNK1DCSNK1A1CSNK1EEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1311507-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016359-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | MAPK14 77/4885CSNK1D 291/4885CSNK1A1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.